Karolinska Development: Modus granted IND
Karolinska Development announced today that Modus Therapeutics has been granted Investigational New Drug (IND) status, paving the way for a phase I trial with a subcutaneous formulation of Sevuparin in the U. S. The announcement was in line with our expectations and will not affect our valuation of Karolinska Development.